In a way......I can't blame them...for waiting until the last minute to annouce a new presentation by invitation.
I wouldn't want a couple of yahoo's disrupting/hijacking my presentation either.
There is a time and a place to address their concerns (which, I might add, contain some legitimate beefs)
Would-be or newbie investors can always go into the Treehouse to factor in the Social Media misinformation, FUD factors, etc. - as they complete their DD.
BTW
Did anyone notice that in the latest presentation, the Revenue opportunity is 33% higher? ($ 2B vs. $ 1.5) ...whereas dilution was around 10% with the last raise? Personally I'd like to hear more about that.
It would seem that it might (partially) have to do with a much higher targeted patient opportunity....up 27% (140,000 patients vs. 110,000 to 120,000 on previous presentations)
Maybe they are factoring in higher incidence of Sepsis (see LA article), or Covid-19 leading to gut translocation and more Sepsis-like endotoxemic reactions?
Any buyer should be kept abreast of the higher (more realistic?) potential...as should existing shareholders.
Using Spectral's $ 2B USD top line, 1X revenue translates to $ 7/sh (pre iDialco value and pre- worldwide EAA Rights) But of course many new drug/device co.s have sold for many times more than 1X revenue. But I still like EBITDA to establish EV.
MM